InMode’s products are part of the medical aesthetics industry that is expected to grow at an 11% CAGR over the next five years. Despite a punishing macro environment of late that has seen its share ...
InMode's stock valuation has fluctuated over time, with high multiples in 2021 due to impressive growth. The company's growth has since slowed down as it has matured. However, current multiples seem ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results